Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
250 | 3813 | 46.8 | 87% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
262 | 3 | AUTOPHAGY//RESVERATROL//HISTONE DEACETYLASE INHIBITOR | 44558 |
2255 | 2 | RESVERATROL//PTEROSTILBENE//TRANS RESVERATROL | 4690 |
250 | 1 | RESVERATROL//TRANS RESVERATROL//PICEID | 3813 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | RESVERATROL | authKW | 8094897 | 56% | 48% | 2125 |
2 | TRANS RESVERATROL | authKW | 835023 | 4% | 63% | 165 |
3 | PICEID | authKW | 446842 | 2% | 72% | 78 |
4 | PICEATANNOL | authKW | 443044 | 3% | 57% | 97 |
5 | STILBENE | authKW | 333494 | 5% | 21% | 201 |
6 | VINIFERIN | authKW | 157732 | 1% | 73% | 27 |
7 | STILBENE SYNTHASE | authKW | 147571 | 1% | 42% | 44 |
8 | RESVERATROL ANALOGUES | authKW | 147162 | 1% | 74% | 25 |
9 | EPSILON VINIFERIN | authKW | 100863 | 1% | 60% | 21 |
10 | CIS RESVERATROL | authKW | 71206 | 0% | 68% | 13 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Food Science & Technology | 4956 | 14% | 0% | 533 |
2 | Pharmacology & Pharmacy | 3106 | 19% | 0% | 711 |
3 | Nutrition & Dietetics | 2789 | 8% | 0% | 293 |
4 | Chemistry, Medicinal | 2560 | 8% | 0% | 318 |
5 | Chemistry, Applied | 1609 | 7% | 0% | 260 |
6 | Agriculture, Multidisciplinary | 1598 | 5% | 0% | 177 |
7 | Oncology | 1152 | 11% | 0% | 418 |
8 | Medicine, Research & Experimental | 751 | 6% | 0% | 243 |
9 | Biochemistry & Molecular Biology | 697 | 16% | 0% | 593 |
10 | Horticulture | 513 | 2% | 0% | 82 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | EA ST S CELLULAIRE PHYSIOPATHOL STRATEGIES NUTR | 32025 | 0% | 100% | 4 |
2 | CLIN PHARM DIAGNOST | 28991 | 1% | 13% | 27 |
3 | GRP ETUD SUBST NAT INTERET THER EUT | 28818 | 0% | 60% | 6 |
4 | FISIOL FARM | 28591 | 0% | 71% | 5 |
5 | NUTR OBES GRP | 28581 | 0% | 36% | 10 |
6 | MYCOL BIOTECHNOL VEGETALE | 28458 | 0% | 44% | 8 |
7 | ANAT COMPARED PATHOL | 25619 | 0% | 80% | 4 |
8 | INVEST BIOMED ENFERMEDADES HEPAT CIBEREHD | 25619 | 0% | 80% | 4 |
9 | FANCL HLTH SCI | 24019 | 0% | 100% | 3 |
10 | LUCIO LASCARAY | 21348 | 0% | 67% | 4 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | MOLECULAR NUTRITION & FOOD RESEARCH | 12445 | 2% | 3% | 59 |
2 | JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY | 6409 | 4% | 1% | 168 |
3 | VITIS | 3377 | 1% | 2% | 24 |
4 | AMERICAN JOURNAL OF ENOLOGY AND VITICULTURE | 2388 | 1% | 1% | 26 |
5 | DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH | 2257 | 1% | 1% | 23 |
6 | JOURNAL OF NUTRITIONAL BIOCHEMISTRY | 2181 | 1% | 1% | 30 |
7 | OXIDATIVE MEDICINE AND CELLULAR LONGEVITY | 1502 | 0% | 1% | 18 |
8 | JOURNAL OF MEDICINAL FOOD | 1303 | 0% | 1% | 18 |
9 | NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL | 1037 | 0% | 1% | 19 |
10 | INTERNATIONAL IMMUNOPHARMACOLOGY | 938 | 1% | 1% | 23 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | RESVERATROL | 8094897 | 56% | 48% | 2125 | Search RESVERATROL | Search RESVERATROL |
2 | TRANS RESVERATROL | 835023 | 4% | 63% | 165 | Search TRANS+RESVERATROL | Search TRANS+RESVERATROL |
3 | PICEID | 446842 | 2% | 72% | 78 | Search PICEID | Search PICEID |
4 | PICEATANNOL | 443044 | 3% | 57% | 97 | Search PICEATANNOL | Search PICEATANNOL |
5 | STILBENE | 333494 | 5% | 21% | 201 | Search STILBENE | Search STILBENE |
6 | VINIFERIN | 157732 | 1% | 73% | 27 | Search VINIFERIN | Search VINIFERIN |
7 | STILBENE SYNTHASE | 147571 | 1% | 42% | 44 | Search STILBENE+SYNTHASE | Search STILBENE+SYNTHASE |
8 | RESVERATROL ANALOGUES | 147162 | 1% | 74% | 25 | Search RESVERATROL+ANALOGUES | Search RESVERATROL+ANALOGUES |
9 | EPSILON VINIFERIN | 100863 | 1% | 60% | 21 | Search EPSILON+VINIFERIN | Search EPSILON+VINIFERIN |
10 | CIS RESVERATROL | 71206 | 0% | 68% | 13 | Search CIS+RESVERATROL | Search CIS+RESVERATROL |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | TOME-CARNEIRO, J , LARROSA, M , GONZALEZ-SARRIAS, A , TOMAS-BARBERAN, FA , GARCIA-CONESA, MT , ESPIN, JC , (2013) RESVERATROL AND CLINICAL TRIALS: THE CROSSROAD FROM IN VITRO STUDIES TO HUMAN EVIDENCE.CURRENT PHARMACEUTICAL DESIGN. VOL. 19. ISSUE 34. P. 6064 -6093 | 236 | 77% | 97 |
2 | AGGARWAL, BB , BHARDWAJ, A , AGGARWAL, RS , SEERAM, NP , SHISHODIA, S , TAKADA, Y , (2004) ROLE OF RESVERATROL IN PREVENTION AND THERAPY OF CANCER: PRECLINICAL AND CLINICAL STUDIES.ANTICANCER RESEARCH. VOL. 24. ISSUE 5A. P. 2783-2840 | 242 | 73% | 768 |
3 | PARK, EJ , PEZZUTO, JM , (2015) THE PHARMACOLOGY OF RESVERATROL IN ANIMALS AND HUMANS.BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. VOL. 1852. ISSUE 6. P. 1071 -1113 | 231 | 66% | 44 |
4 | BAUR, JA , SINCLAIR, DA , (2006) THERAPEUTIC POTENTIAL OF RESVERATROL: THE IN VIVO EVIDENCE.NATURE REVIEWS DRUG DISCOVERY. VOL. 5. ISSUE 6. P. 493-506 | 137 | 63% | 1725 |
5 | HARIKUMAR, KB , AGGARWAL, BB , (2008) RESVERATROL - A MULTITARGETED AGENT FOR AGE-ASSOCIATED CHRONIC DISEASES.CELL CYCLE. VOL. 7. ISSUE 8. P. 1020 -1035 | 172 | 77% | 255 |
6 | NEVES, AR , LUCIO, M , LIMA, JLC , REIS, S , (2012) RESVERATROL IN MEDICINAL CHEMISTRY: A CRITICAL REVIEW OF ITS PHARMACOKINETICS, DRUG-DELIVERY, AND MEMBRANE INTERACTIONS.CURRENT MEDICINAL CHEMISTRY. VOL. 19. ISSUE 11. P. 1663 -1681 | 202 | 64% | 85 |
7 | ZORDOKY, BNM , ROBERTSON, IM , DYCK, JRB , (2015) PRECLINICAL AND CLINICAL EVIDENCE FOR THE ROLE OF RESVERATROL IN THE TREATMENT OF CARDIOVASCULAR DISEASES.BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. VOL. 1852. ISSUE 6. P. 1155 -1177 | 179 | 60% | 23 |
8 | PEZZUTO, JM , (2008) RESVERATROL AS AN INHIBITOR OF CARCINOGENESIS.PHARMACEUTICAL BIOLOGY. VOL. 46. ISSUE 7-8. P. 443 -573 | 271 | 60% | 31 |
9 | SAIKO, P , SZAKMARY, A , JAEGER, W , SZEKERES, T , (2008) RESVERATROL AND ITS ANALOGS: DEFENSE AGAINST CANCER, CORONARY DISEASE AND NEURODEGENERATIVE MALADIES OR JUST A FAD?.MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH. VOL. 658. ISSUE 1-2. P. 68-94 | 136 | 77% | 226 |
10 | PERVAIZ, S , HOLME, AL , (2009) RESVERATROL: ITS BIOLOGIC TARGETS AND FUNCTIONAL ACTIVITY.ANTIOXIDANTS & REDOX SIGNALING. VOL. 11. ISSUE 11. P. 2851 -2897 | 204 | 48% | 208 |
Classes with closest relation at Level 1 |